Physician profile
Scott E Jenkins
NPI 1528009743
$840.07
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $139 · 2021: $56.35.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $246.19 | 2019-2020 | |
| Pfizer INC. | $244.08 | 2019-2021 | |
| Amarin Pharma, INC. | $89.91 | 2019-2020 | |
| Amgen INC. | $67.13 | 2019 | |
| Sanofi Pasteur INC. | $36.03 | 2019 | |
| Merck Sharp & Dohme LLC | $28.36 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.42 | 2019 | |
| Astellas Pharma US INC | $22.71 | 2019 | |
| Lilly USA, LLC | $18.80 | 2019 | |
| Novo Nordisk INC | $18.56 | 2019 | |
| Allergan, INC. | $15.69 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.62 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.